← themes
Healthcare & life sciences
appeared in 21 sessions · 15 labels · 27 names · 2026-07-14 → 2026-09-14
One driver, every session the wrap named it in — newest first. The wrap writes its own heading each day, so the wording below changes constantly while the driver underneath doesn't.
What it's been called
Healthcare DislocationsHealthcare DisappointmentsOncology Reality CheckOncology Paradigm ShiftBiotech's Paradigm ShiftHistoric Oncology BreakthroughsHealthcare & Biotech Reality ChecksHistoric Milestone for Personalised OncologyHealthcare Milestones & FrictionHealthcare DivergenceDefensive Growth & The Life Sciences ReboundHealthcare Volatility and Biotech ContagionMedTech & Freight Flex MuscleMargin Squeeze in Insurance and Managed CareHealthcare Headwinds and Biotech Blowups
Names in this category
Healthcare Dislocations
COOThe Cooper Companies, Inc.The stock plunged after Q3 revenue missed estimates, forward guidance was cut, and the planned CooperSurgical spin-off was canceled.AMGNAmgen Inc.Shares dropped after competitor Novartis reported a Phase 3 trial failure for a drug targeting the same cardiovascular biomarker.
Healthcare Dislocations
Healthcare Dislocations
COOThe Cooper Companies, Inc.The stock dropped due to a Q3 revenue miss, slashed full-year guidance from inventory destocking, and the retention of CooperSurgical.AMGNAmgen Inc.Amgen fell due to a rival's drug trial failure impacting its pipeline, analyst downgrades, and regulatory suspensions of Tavneos.SYKStryker CorporationPersistent peripheral vascular supply disruptions and softer orthopedic volumes triggered guidance cuts and a steep sell-off.ELVElevance Health, Inc. (formerly Anthem, Inc.)Elevance reaffirmed its FY2026 earnings guidance in an 8-K filing and noted Q3 adjusted earnings are tracking ahead of expectations.
Healthcare Disappointments
Oncology Reality Check
Oncology Paradigm Shift
Biotech's Paradigm Shift
Historic Oncology Breakthroughs
MRKMerck & Co., Inc.Merck and Moderna reported positive Phase 3 results for an mRNA cancer vaccine with KEYTRUDA in high-risk melanoma.MRNAModerna, Inc.Moderna and Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine in high-risk melanoma patients.HCAHCA Healthcare, Inc.The stock surged following analyst price target adjustments, institutional 13F accumulation, and strategic technology updates.
Healthcare & Biotech Reality Checks
MRNAModerna, Inc.Moderna fell 23.55% on profit-taking and valuation resets after a 177% rally driven by Phase 3 cancer vaccine trial results.ISRGIntuitive Surgical, Inc.The stock fell due to CapEx and margin concerns from a Malaysia expansion, insider share sales disclosures, and macro healthcare pressures.BSXBoston Scientific CorporationSector-wide MedTech selling triggered technical profit-taking following consecutive guidance cuts and slowing U.S. growth engines.
Historic Milestone for Personalised Oncology
Healthcare Milestones & Friction
MRNAModerna, Inc.Moderna stock surged due to FDA approval of its mRNA flu vaccine, a Q2 earnings beat, reduced expense guidance, and institutional buying.CORCencora, Inc.Shares fell after an 8-K filing revealed non-prime Walgreens pharmaceutical distribution volume began shifting to external distributors.
Healthcare Divergence
DVADaVita Inc.DaVita reported a full-year guidance midpoint that missed consensus estimates alongside sequential declines in revenue per treatment.CRLCharles River Laboratories International, Inc.Shares surged after Charles River reported strong Q2 2026 earnings, returned to organic revenue growth, and raised full-year guidance.PODDInsulet CorporationInsulet lowered full-year 2026 revenue guidance due to high customer churn during Type 2 diabetes patient onboarding.VRTXVertex Pharmaceuticals IncorporatedVertex rose on strong Q2 earnings, raised full-year guidance, and the trial failure of a key rival's cystic fibrosis drug candidate.CVSCVS Health CorporationCVS stock fell due to cautious 2027 guidance, H2 profit pull-forwards into Q2, and regulatory concerns surrounding 340B drug rebates.
Healthcare Divergence
DVADaVita Inc.DaVita fell after reaffirming full-year guidance despite Q2 beats, as ACA subsidy expirations caused margin compression.CRLCharles River Laboratories International, Inc.CRL surged following strong Q2 2026 earnings, a return to positive organic revenue growth, raised full-year guidance, and analyst upgrades.
Healthcare Divergence
Healthcare Divergence
PODDInsulet CorporationInsulet lowered its 2026 revenue guidance due to high patient attrition and low utilization among Type 2 diabetes users.DVADaVita Inc.The stock fell as Q2 revenue per treatment dropped from an adverse ACA payer mix shift and full-year EPS guidance was merely reconfirmed.CRLCharles River Laboratories International, Inc.CRL stock surged following a strong Q2 2026 earnings beat and an across-the-board upward revision to full-year 2026 financial guidance.
Defensive Growth & The Life Sciences Rebound
TMOThermo Fisher Scientific Inc.Thermo Fisher stock surged 8.71% after beating Q2 earnings estimates and raising its full-year 2026 guidance.DGXQuest Diagnostics IncorporatedQuest Diagnostics beat Q2 2026 earnings estimates on revenue and EPS and raised its full-year 2026 guidance.DHRDanaher CorporationDanaher surged 7.46% as strong peer earnings from Thermo Fisher validated a life sciences recovery after an overdone sell-off.
Healthcare Volatility and Biotech Contagion
MRNAModerna, Inc.Moderna fell due to Danaher's weak earnings dragging biotechs lower, pre-catalyst investor de-risking, and new patent litigation.ABTAbbott LaboratoriesAbbott stock surged after Q2 earnings beat expectations and management raised full-year EPS guidance.ISRGIntuitive Surgical, Inc.ISRG dropped as slowing U.S. surgical procedure growth, conservative guidance, and margin warnings overshadowed a Q2 earnings beat.
Healthcare Divergence
ISRGIntuitive Surgical, Inc.The stock fell after management kept full-year procedure growth guidance unchanged despite beating Q2 revenue and EPS estimates.MRNAModerna, Inc.JPMorgan placed MRNA on its Top Short Ideas list due to valuation over-expansion, cash burn, and a missed flu contracting window.ABTAbbott LaboratoriesAbbott beat Q2 earnings estimates, raised full-year profit guidance, and the DOJ closed its criminal infant formula investigation.ELVElevance Health, Inc.Q2 earnings beat was driven by non-recurring items while core health margins compressed and Medicaid losses led to market exits.
MedTech & Freight Flex Muscle
ABTAbbott LaboratoriesAbbott surged following strong Q2 2026 earnings and revenue beats, raised full-year guidance, and solid growth in Medical Devices.JBHTJ.B. Hunt Transport Services, Inc.Shares surged after Q2 2026 earnings and revenue beat Wall Street estimates due to strong intermodal volume and margin expansion.FDXFFedEx Freight Holding Company, Inc.The stock surged following a bullish analyst initiation from Citizens JMP and industry data confirming tightening freight capacity.CTASCintas CorporationCintas stock rose following strong Q4 earnings, record gross margins, robust FY2027 guidance, and a new $1.0 billion share buyback.DXCMDexCom, Inc.The stock rose on analyst price target upgrades, strong peer earnings from Abbott, and Canadian authorization for the Dexcom G7.
Margin Squeeze in Insurance and Managed Care
ERIEErie Indemnity CompanyThe stock fell due to a P&C sector selloff, pre-earnings anxiety over slowing growth, and a quantitative screen downgrade.PGRThe Progressive CorporationJune net income fell 31% YoY as the combined ratio spiked to 90.0% due to rising loss severity in personal auto lines.ELVElevance Health, Inc.Stock fell 8.54% after Q2 earnings revealed low quality beat, severe Medicaid margin compression, and an implied 2H guidance downgrade.
Healthcare Headwinds and Biotech Blowups
MRNAModerna, Inc.Moderna fell due to a JP Morgan Sell rating, slashed Q2 revenue guidance, and a $950 million patent settlement cash outflow.AZN.LAstraZeneca PLCThe stock fell after Wainua failed to meet its primary efficacy endpoint in a Phase III trial for ATTR-CM.BIIBBiogen Inc.Biogen stock fell 8.17% after Phase 2 data for Alzheimer's drug diranersen showed an inverted dose-response anomaly.HCAHCA Healthcare, Inc.HCA lowered its full-year 2026 guidance after the expiration of ACA tax credits drove a shift to uninsured status.ISRGIntuitive Surgical, Inc.HCA Healthcare reported declining surgical volumes, sparking fears of slowing procedure growth for Intuitive Surgical.